Please assess the completion status of the following clinical trial:

Trial Title: Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have a known diagnosis of Familial Adenomatous Polyposis (FAP) and have had a previous colectomy with ileo-rectal anastomosis.~* Males or females aged 18 and over~* If the participant is female and of child bearing potential, she agrees to participate in this study by providing written informed consent, has been using adequate contraception (e.g. abstinence, condom, Intra-uterine device (IUD), birth control pill, diaphragm and spermicidal gel combination) since her last menses and will use adequate contraception during the study, is not lactating, and agrees to undergo a serum pregnancy test at baseline and month 6. Sexually active males must agree to use an accepted method of contraception.~* Rectal polyp status: the subject has an endoscopically assessable rectal segment.~* Subjects must show a willingness to abstain from regular use of non-steroidal anti-inflammatory medication for the duration of the study. A cardioprotective dose of aspirin (75mg) will be permitted.~* Subjects must have provided written informed consent to participate.~* Subjects must have assessable rectal polyps post baseline flexible sigmoidoscopy.~* Subjects must have the following rectal polyp burden at the conclusion of the baseline endoscopy:~* Rectum - 3 or more quantifiable polyps ≥2mm diameter~* In the rectum quantifiable polyps are defined as being within a composite cloverleaf photograph that includes a tattoo.~Exclusion Criteria:~* Subjects who are due to undergo an anticipated colectomy within 8 months of randomisation~* History of invasive carcinoma in the past 5 years other than resected Dukes' A/B1 colon cancer or resected non-melanomatous skin cancer~* Partial or complete colectomy within 12 months prior to enrolment.~* History of pelvic radiation~* Subjects who are allergic to fish~* Subjects who have diabetes mellitus~* Subjects who are pregnant or breast-feeding~* Subjects taking aspirin or other non-steroidal anti-inflammatory drugs on a regular basis other than low dose (75 mg) cardioprotective dose.~* Subjects who have aspirin-sensitive asthma~* Subjects suffering from haemorrhagic disorders~* Subjects who are taking warfarin or other anticoagulants~* Subjects who have significant abnormalities on their screening blood tests~* Subjects taking lipid lowering medication~* Subjects with gastrointestinal malabsorptive disease~* Subjects with known or prior coagulopathy~* Subjects with uncontrolled hypercholesterolaemia~* Subjects who are taking other fish-oil supplements (e.g. cod liver oil) who are unwilling to stop them for the duration of the study. Subjects previously taking fish oil must have a washout period of 1 month prior to study enrolment.~* Subjects who are deemed mentally incompetent, or have a history of anorexia nervosa or bulimia~* Subjects with a history of alcohol or drug abuse, including laxative abuse which would render the subject unreliable.~* Subjects considered by their physician unlikely to be able to comply with the protocol.~* Subjects who have taken part in an experimental drug study in the preceding 3 months.~* Subjects who have a positive pregnancy test within 14 days prior to baseline visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 2g/day Eicosapentanoic Acid (EPA) (Type: EXPERIMENTAL): Eicosapentanenoic Acid (EPA) as the free fatty acid 2 capsules twice daily for 6 months.~Endoscopy and biopsies taken as described under intervention.
- Placebo (Type: PLACEBO_COMPARATOR): Medium chain triglycerides 2 capsules twice daily for six months. Endoscopy and biopsies taken as described under intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).